Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.55 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PREP | P48147 | 3/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.47 |
| ▸ | FAP | Q12884 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26616542 | 1.00 | ACE (0.55) | ACEERAP2ERAP1LNPEPLMNA | |
| SCHEMBL26616508 | 0.89 | ACE (0.59) | ACEERAP2ERAP1LNPEPLMNA | |
| SCHEMBL26616515 | 0.89 | ACE (0.59) | ACEERAP2ERAP1LNPEPLMNA | |
| SCHEMBL5967094 | 0.88 | ACE (0.52) | ACELMNAPREPLTA4HFAP | |
| SCHEMBL31376312 | 0.87 | ACE (0.57) | ACEERAP2ERAP1LNPEPLMNA | |
| SCHEMBL30674426 | 0.87 | ACE (0.57) | ACEERAP2ERAP1LNPEPLMNA | |
| SCHEMBL26616536 | 0.87 | ACE (0.57) | ACEERAP2ERAP1LNPEPLMNA | |
| SCHEMBL26616543 | 0.87 | ACE (0.57) | ACEERAP2ERAP1LNPEPLMNA | |
| SCHEMBL10655628 | 0.87 | ACE (0.59) | ACELMNALTA4HACE2 | |
| SCHEMBL26616582 | 0.86 | ACE (0.56) | ACEERAP2ERAP1LNPEPLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288559-A1 | PREP BINDING LIGANDS | POLKU THERAPEUTICS OY (FI) | 2025-09-18 | — | — | US | disclosed |
| EP-4514781-A1 | PREP BINDING LIGANDS | Polku Therapeutics OY (FI) | 2025-03-05 | — | — | EP | disclosed |
| CN-119451944-A | PREP binding ligands | 珀尔库治疗有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2023209191-A1 | PREP BINDING LIGANDS | UNIVERSITY OF HELSINKI (FI) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288559-A1 | PREP BINDING LIGANDS | PREP, ERAP2, CTSA | ACE 1037/4885ERAP2 2/4885ERAP1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.